West Pharmaceutical Services, Inc.

NYSE:WST

Medical - Instruments & Supplies

Healthcare
$404.02 +1.56%

+$5.04 today

Market cap
$28.14B
Beta
1.18
P/E (TTM)
43.6
EPS (TTM)
$7.54
Dividend yield
0.26%
52W Low $206.80High $336.82

Volume 0.59M

Average 0.85M

WST EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

West Pharmaceutical Services, Inc.NYSE: WST

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows in line with its trailing trend

Q2 FY2026 EBITDA of $225.3M rose 13.5% year over year, behind the +14.5% change in trailing-twelve-month EBITDA. Sequentially, it rose 3.1% from the prior quarter. Over 3 fiscal years it compounded at -1.6% a year.

Context

  • EBITDA amounted to 25.1% of revenue in FY2025, down 0.6 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 12 analysts of $1.03B (+33.6%) for the fiscal year ending Dec 2026, a step up from the +3.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$225.3M+3.1% QoQ
Last fiscal yearDec 2025
$770.6M+3.6% YoY
LTMJun 2026
$870.4M+14.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.5%+7.6%-5.9 pp
1 year+3.6%+33.6%+30.0 pp
3-year CAGR-1.6%+18.5%+20.1 pp
5-year CAGR+15.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
770.6M USD
Year-over-year change
+3.6%
4-year CAGR
-3.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How WST compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.5% is the highest of 5, against a peer median of -13.9%.
  • EBITDA amounts to 26.2% of revenue for WST, versus a peer median of 16.2%.
WST Competitors
EBITDA for WST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$870.4M USD+14.5%-1.6%26.2%
ATRAptarGroup, Inc.LTM Jun 2026$822.22M USD+1.7%+10.9%20.9%
STVNStevanato Group S.p.A.LTM Jun 2026€296.36M EUR-4.5%+4.4%24.3%
ICUIICU Medical, Inc.LTM Jun 2026$247.61M USD-23.3%+17.3%11.5%
BLFSBioLife Solutions, Inc.LTM Mar 2026-$7.46M USD-184.6%—7.5%
Peer median (excluding WST) —-13.9%+10.9%16.2%

Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.83B2.89B2.95B2.89B3.07B
Cost of Revenue1.66B1.75B1.82B1.89B1.97B
Gross Profit1.17B1.14B1.13B1B1.1B
Gross Margin41.5%39.5%38.4%34.6%35.9%
Research & Development52.8M58.5M68.4M69.1M74.3M
Selling, General & Admin361.9M316.9M353.4M338.5M393.1M
Operating Expenses414.7M375.4M421.8M407.6M485.9M
Depreciation & Amortization122.3M120.6M137.3M155.4M171.4M
EBITDA879.7M808.1M844.1M743.8M770.6M
EBITDA Margin31.1%28.0%28.6%25.7%25.1%
Operating Income758.7M763.5M710.9M594.6M617.4M
Operating Margin26.8%26.5%24.1%20.6%20.1%
Interest Income1M5.1M28M19.6M17.7M
Interest Expense8.5M7.6M8.8M2.9M600K
Other Income / Expenses10.3M(62.9M)4.8M5.6M(2.1M)
Income Before Tax769M700.6M715.7M600.2M615.3M
Pre-Tax Margin27.2%24.3%24.3%20.7%20.0%
Income Tax Expense107.2M114.7M122.3M107.5M121.6M
Net Income661.8M585.9M593.4M492.7M493.7M
Net Margin23.4%20.3%20.1%17.0%16.1%
EPS (Basic)8.907.887.996.756.83
EPS (Diluted)8.677.737.886.696.80
Weighted Avg Shares74.4M74.4M74.3M73M72.3M
Weighted Avg Shares (Diluted)76.3M75.8M75.3M73.7M72.7M

West Pharmaceutical Services, Inc.

NYSE:WST

Intrinsic Alpha fair value

Locked

Current Price

$404.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.